generalised myasthenia gravis
Neurology · 2024–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| efgartigimod alfa Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. | Mar 2026 | Recommended with restriction | input received Myasthenia Alliance Australia |
| rozanolixizumab Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. | Mar 2025 | Recommended with restriction | 17 individuals Myasthenia Alliance Australia |
| zilucoplan Treatment of generalised myasthenia gravis (gMG) in adult patients with anti-acetylcholine receptor (AChR) antibody positive disease who are refractory to… | Mar 2025 | Recommended with restriction | input received Myasthenia Alliance Australia |
| efgartigimod alfa Add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody… | Nov 2025 | Recommended with restriction | 10 individuals Myasthenia Alliance Australia |
| rozanolixizumab Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. | Nov 2025 | Recommended with restriction | 17 individuals Myasthenia Alliance Australia |
| ravulizumab Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and remain symptomatic… | Jul 2024 | Not recommended | 36 individuals Myasthenia Alliance Australia · Myasthenia Gravis Association of Queensland |
| zilucoplan Treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. | Jul 2024 | Not recommended | 31 individuals Myasthenia Alliance Australia |
Who spoke
Myasthenia Alliance Australia · Myasthenia Gravis Association of Queensland
What the PBS pays
$106M in government benefit over 2024–25, across 1,691 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ravulizumab | $105.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 1 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| rozanolixizumabRozanolixizumab for treating antibody-positive generalised myasthenia gravis | TA1155 | recommended restricted | 2026-05 |
| efgartigimodEfgartigimod for treating antibody-positive generalised myasthenia gravis | TA1069 | not recommended | 2025-06 |
| ravulizumabRavulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | terminated | 2023-12 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.